Comparative Pharmacology
Head-to-head clinical analysis: OPTIRAY 160 versus OPTIRAY 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTIRAY 160 versus OPTIRAY 320.
OPTIRAY 160 vs OPTIRAY 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque contrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and organs during imaging procedures.
Iodinated radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast during radiographic procedures.
Intravenous: 50-150 mL (total dose 8-30 g iodine) as a bolus or rapid infusion; Intra-arterial: Variable per procedure; maximum 250 mL per procedure.
Intravenous administration: 50-150 mL of OPTIRAY 320 (ioversol 320 mg iodine/mL) per injection for contrast-enhanced CT; total dose not to exceed 250 mL. Intra-arterial: variable per procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 to 2 hours in patients with normal renal function. Prolonged in renal impairment, up to 20–30 hours in severe renal failure.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >60 mL/min). Prolonged in renal impairment; may exceed 20 hours in severe renal failure (CrCl <30 mL/min).
Primarily renal excretion via glomerular filtration; approximately 95% of the administered dose is excreted unchanged in the urine within 24 hours. Fecal excretion is negligible (<1%).
Renal excretion of unchanged drug via glomerular filtration; approximately 95% eliminated in urine within 24 hours. Less than 1% excreted in feces via biliary route.
Category C
Category C
Radiological Contrast Agent
Radiological Contrast Agent